請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60198
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蘇璧伶 | |
dc.contributor.author | Bo-Hui Huang | en |
dc.contributor.author | 黃柏惠 | zh_TW |
dc.date.accessioned | 2021-06-16T10:13:32Z | - |
dc.date.available | 2018-08-29 | |
dc.date.copyright | 2013-08-29 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-19 | |
dc.identifier.citation | Abelson, A., Shelton, D., Whelan, M., 2009, Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs. J Vet Emerg Crit Care, 19, 369–374.
Allenspach, K., Wieland, B., Grone, A., Gaschen, F., 2007, Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med, 21, 700-708. Angles, J.M., Kennedy, L.J., Pedersen, N.C., 2005, Frequency and distribution of alleles of canine MHC-II DLADQB1,DLA-DQA1 and DLA-DRB1 in 25 representative American Kennel Club breeds. Tissue Antigens, 66, 173-184. Barcellini, W., Clerici, G., Montesano, R., Taioli, E., Morelati, F., Rebulla, P., Zanella, A., 2000, In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation. Br J Haematol, 452-460. Barker, R.N., Gruffydd-Jones, T.J., Stokes, C.R., Elson, C.J., 1991, Identification of autoantigens in canine autoimmune haemolytic anaemia. Clin Exp Immunol, 85, 33-40. Bloom, J.C., Thiem, P.A., Sellers T.S., Deldar A, Lewis H.B., 1998, Cephalosporin-induced immune cytopenia in the dog: demonstration of erythrocyte-, neutrophil-, and platelet-associated IgG following treatment with cefazedone. Am J Hematol, 28, 71-78. Breuhl, E.L., Moore, G., Brooks, M.B., Scott-Moncrieff, J.C., 2009, A prospective study of unfractionated heparin therapy in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc, 45, 125-133. Burgess, K., Moore, A., Rand, W., Cotter, S.M., 2000, Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med, 14, 456-462. Bussel, J.B., Cunningham-Rundles, C., Abraham, C., 1986, Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang, 51, 264-269. Carr, A.P., Panciera, D.L., Kidd, L., 2002, Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med, 16, 504-509. Chen, W.C., Su, B.L., Jeng, C.R., 2009, The significances of antiglobulin test in dogs with immune-mediated hemolytic anemia. Taiwan Vet J, 35, 233-240. Corato, A., Shen, C.R., Mazza, G., Barker, R.N., Day, M.J., 1997, Proliferative responses of peripheral blood mononuclear cells from normal dogs and dogs with autoimmune haemolytic anaemia to red blood cell antigens. Vet Immunol Immunopathol, 59, 191-204. Creed, T.J., Lee, R.W., Newcomb, P.V., di Mambro, A.J., Raju, M., Dayan, C.M., 2009, The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. J Immunol, 183, 164-171. Darabi, K., Abdel-Wahab, O., Dzik, W.H., 2006, Current usage of intravenous immune globulin and the rationale behind it. Transfusion, 46, 741–753. Day, M.J., 1999, Antigen specificity in canine autoimmune haemolytic anaemia. Vet Immunol Immunopathol, 69, 215-224. Duval, D., Giger, U., 1996, Vaccine-associated immune-mediated hemolytic anemia in the dog. J Vet Intern Med, 10, 290-295. Emmi, L., Chiarini, F., 2002, The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci, 23, 1-8. Fagiolo, E., 2004, Immunological tolerance loss vs. erythrocyte self antigens and cytokine network disregulation in autoimmune hemolytic anaemia. Autoimmun Rev, 3, 53-59. Feldman, B.F., Handagama, P., Lubberink, A.A., 1985, Splenectomy as adjunctive therapy for immune-mediated thrombocytopenia and hemolytic anemia in the dog. J Am Vet Med Assoc, 187, 617-619. Fenty, R.K., Delaforcade, A.M., Shaw, S.E., O’Toole, T.E., 2011, Identification of hypercoagulability in dogs with primary immune-mediated hemolytic anemia by means of thromboelastography. J Am Vet Med Assoc, 238, 463-467. Fleming, J.M., Creevy, K.E., Promislow, D.E.L., 2011, Mortality in North American dogs from 1984 to 2004: An investigation into age-, size-, and breed-related causes of death. J Vet Intern Med, 25, 187–198. Frank, J.R., Breitschwerdt, E.B.,1999, A retrospective study of ehrlichiosis in 62 dogs from North Carolina andVirginia. J Vet Intern Med, 13, 194-201. Frank, M.M., 1977, Pathophysiology of immune hemolytic anemia. Ann Intern Med, 87, 210-222. Giger, U., 2005, Regenerative anemia Caused by Blood Loss or Hemolysis. Pp 1886- 1907. In: Ettinger JE, Feldman, E.C(eds), Textbook of Veterinary Internal Medicine, 6. WB Saunders, Philadelphia, PA. Griebsch, C., Arndt, G., Raila, J., Schweigert, F.J., Kohn, B., 2009, C-reactive protein concentration in dogs with primary immune-mediated hemolytic anemia. Vet Clin Pathol, 38, 421-425. Grundy, S.A., Barton, C., 2001, Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). J Am Vet Med Assoc, 218,543-546. Helmond, S.E., Polzin, D.J., Armstrong, P.J., Finke, M., Smith, S.A., 2010, Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs. J Vet Intern Med, 24, 597-605. Holahan, M.L., Brown, A.J., Drobatz, K.J., 2010, The association of blood lactate concentration with outcome in dogs with idiopathic immune-mediated hemolytic anemia: 173 cases (2003-2006). J Vet Emerg Crit Care, 20, 413-420. Husbands, B., Polzin, D., Armstrong, P.J., Cohn, L. and Patterson, N.E., 2004, Prednisone and cyclosporine vs prednisone alone for treatment of canine immune mediated hemolytic anemia. J Vet Intern Med, 18, 389. Ishihara, M., Fujino, Y., Setoguchi, A., Takahashi, M., Nakashima, K., Ohno, K., 2010, Evaluation of prognostic factors and establishment of a prognostic scoring system for canine primary immune-mediated hemolytic anemia. J Vet Med Sci, 72, 465-470. Jones, D.R., Gruffydd-Jones, T.J., Stokes, C.R., Bourne, F.J., 1990, Investigation into factors influencing performance of the canine antiglobulin test. Res Vet Sci, 48, 53-58. Jones, D.R., Stokes, C.R., Gruffydd-Jones, T.J., Bourne, F.J., 1987, An enzyme-linked antiglobulin test for the detection of erythrocyte- bound antibodies in canine autoimmune haemolytic anaemia. Vet Immunol Immunopathol, 16, 11-21 Jonas, L.D., Thrall, M.A., Weiser, M.G., 1987, Nonregenerative form of immune-mediated hemolytic anemia in dogs. J Am Anim Hosp Assoc, 23, 201 - 204. Kazatchkine, M.D., Kaveri, S.V., 2001, Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med, 345, 747–755. Keller, E.T., 1992, Immune-mediated disease as a risk factor for canine lymphoma. Cancer, 70, 2334-2337. Kellerman, D.L. and Bruyette, D.S., 1997, Intravenous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs. J Vet Intern Med, 11, 327-332. Klag, A.R., Giger, U., Shofer, F.S., 1993, Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). J Am Vet Med Assoc, 202, 783-788. Klein, M.K., Dow, S.W., Rosychuk, R.A., 1989, Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). J Am Vet Med Assoc, 195, 246-250. Lapierre, Y., Rigal, D., Adam, J., Josef, D., Meyer, F., Greber, S., 1990, The gel test: a new way to detect red cell antigen-antibody reactions. Transfusion (Paris), 30, 109-113. Lemiwux, R., Bazin, R., Neron, S.,2005, Therapeutic intravenous immunoglobulins. Mol Immunol, 42, 839–848. Mason, N., Duval, D., Shofer, F.S., Giger, U., 2003, Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune-mediated hemolytic anemia in dogs: a randomized controlled clinical trial. J Vet Intern Med, 17, 206-212. Mathes, M., Jordan, M. and Dow, S., 2006, Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs. Exp Hematol, 34, 1393-1402 McAlees, T.J., 2010, Immune-mediated haemolytic anaemia in 110 dogs in Victoria, Australia. Aust Vet J, 88, 25-28. Mehling, A., Grabbe, S., Voskort, M., Schwarz, T., Luger, T.A., Beissert, S., 2000, Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol, 165, 2374-2381. Mellor, P.J., Roulois, A.J., Day, M.J., Blacklaws, B.A., Knivett, S.J., Herrtage, M.E., 2005, Neutrophilic dermatitis and immune-mediated haematological disorders in a dog: suspected adverse reaction to carprofen. J Small Anim Pract, 46, 237-242. Miller, D.L., Yaron, R., Yellin, M.J., 1998, CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol, 63, 373-379. Miller, S.A., Hohenhaus, A.E., Hale, A.S., 2004, Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc, 224, 232-235. Mitchell, K.D., Kruth, S.A., Wood, R.D., Jefferson, B., 2009, Serum acute phase protein concentrations in dogs with autoimmune hemolytic anemia. J Vet Intern Med, 23, 585-59 Morita, T., Saeki, H., Imai, S., Ishii, T., 1995, Reactivity of anti-erythrocyte antibody induced by Babesia gibsoni infection against aged erythrocytes. Vet Parasitol, 58, 291-299. Morley, P., Mathes, M., Guth, A., Dow, S., 2008, Anti-erythrocyte antibodies and disease associations in anemic and nonanemic dogs. J Vet Intern Med, 22, 886-892. Noble, S.J., Armstrong, P.J.,1999, Bee sting envenomation resulting in secondary immune-mediated hemolytic anemia in two dogs. J Am Vet Med Assoc 214,1026-1027, 1021. Orcutt, E.S., Lee, J.A., Bianco, 2010, Immune-mediated hemolytic anemia and severe thrombocytopenia in dogs: 12 cases (2001-2008). J Vet Emerg Crit Care (San Antonio), 20, 338-345. Piek, C.J., Brinkhof , B., Teske, E., Rothuizen, J., Dekker, A., Penning, L., 2011, High intravascular tissue factor expression in dogs with idiopathic immune-mediated haemolytic anaemia.Vet Immunol Immunopathol, 144, 346-354. Piek, C.J., Junius, G., Dekker, A., Schrauwen, E., Slappendel, R.J., Teske, E., 2008, Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med, 22, 366-373. Piek, C.J., van Spil, W.E., Junius, G., Dekker, A., 2011, Lack of evidence for a beneficial effect of azathioprine in dogs treated with prednisolone for idiopathic immune-mediated haemolytic anaemia: a retrospective cohort study. BMC Vet Res, 7-15. Reagan, W.J., Scott-Moncrieff, C., Christian, J., Snyder, P., Kelly, K., Glickman, L, 1998, Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes. Am J Vet Res, 59, 1568-1574. Reimer, M.E., Troy, G.C., Warnick, L.D., 1999, Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc, 35, 384-391. Ridyard, A.E., Shaw, D.J., Milne, E.M., 2010, Evaluation of platelet activation in canine immune-mediated haemolytic anaemia. J Small Anim Pract, 51, 296-304. Rother, R.P., Bell, L., Hillmen, P., Gladwin, M.T., 2005, The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. J Am Vet Med Assoc, 293, 1653-1662. Scott-Moncreiff, J.C., Reagan, J.W., Glickman, L.T., 1995, Treatment of nonregenerative anemia with human gamma-globulin in dogs. J Am Vet Med Assoc, 206, 1895–1900. Scott-Moncrieff, J.C., Reagan, W.J., Snyder, P.W. and Glickman, L.T., 1997, Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc, 210, 1623-1627. Scott-Moncrieff, J.C., Treadwell, N.G., McCullough, S.M., Brooks, M.B., 2001, Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc, 37, 220-227. Spurlock, N.K., Prittie, J.E., 2011, A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin. J Vet Emerg Crit Care, 21, 471–483. Stokol, T., Blue, J.T., French, T.W., 2000, Idiopathic pure red cell aplasia and nonregenerative immune-mediated anemia in dogs: 43 cases (1988-1999). J Am Vet Med Assoc, 216, 1429-1436. Swann, J.W., Skelly, B.J., 2011, Evaluation of immunosuppressive regimens for immune-mediated haemolytic anaemia: a retrospective study of 42 dogs. J Small Anim Pract, 52, 353–358. Tha-In, T., Bayry, J., Metselaar, H.J., Kaveri, S.V. and Kwekkeboom, J., 2008, Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol, 29, 608-615 Thompson, M.F., Scott-Moncrieff, J.C., Brooks, M.B., 2004, Effect of a single plasma transfusion on thromboembolism in 13 dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc, 40, 446-454. Tsuchiya, R., Akutsu, Y., Scott, M.A., 2009, Prothrombotic and inflammatory effects of intravenous administration of human immunoglobulin G in dogs. J Vet Intern Med, 23, 1164–1169. Vaccaro, J., Zhou, J., Ober, R.J., 2005, Engineering the Fc region of immunoglobulin G to modulate en vivo antibody levels. Nat Biotechnol, 23, 1283–1288 Wardrop, K.J., 2005, The Coombs’ test in veterinary medicine: past, present, future. Vet Clin Pathol, 34, 325-334. Warman, S.M., Murray, J.K., Ridyard, A., Eastwood, J., Silva, S., Day, M.J., 2008, Pattern of Coombs’ test reactivity has diagnostic significance in dogs with immune-mediated haemolytic anaemia. J Small Anim Pract, 49, 525-530. Weinkle, T.K., Center, S.A., Randolph, J.F., Warner, K.L., Barr, S.C., Erb, H.N., 2005, Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc, 226, 1869-1880. Weiss, D.J., 2002, Primary pure red cell aplasia in dogs: 13 cases (1996-2000). J Am Vet Med Assoc, 221, 93-95. Weiss, D.J., 2008, Bone marrow pathology in dogs and cats with non-regenerative immune-mediated haemolytic anaemia and pure red cell aplasia. J Comp Pathol, 138, 46-53. Weiss, D.J., Brazzell, J.L., 2006, Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med, 20, 682-686. Whitley, N.T., Day, M.J., 2011, Immunomodulatory drugs and their application to the management of canine immune-mediated disease, J Small Anim Pract , 52, 70–85. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60198 | - |
dc.description.abstract | 犬免疫性溶血性貧血(Immune-mediated hemolytic anemia;IMHA)為犬隻常見的貧血疾病之一。在臨床醫療上,由於患犬常在免疫抑制藥物發生作用前,便因病情迅速惡化導致死亡,因此找尋一個能快速穩定動物病情的治療方式,便顯得非常重要。本研究的目的為針對較嚴重的病例,分析其基本資料、臨床表現與治療期間一系列血液學檢查,找出影響預後的因子及評估治療中加入靜脈注射人類免疫球蛋白(human intravenous immunoglobulin; hIVIG)的效果,做為未來臨床治療上的參考。
本研究收集2006年4月至2013年4月間至台大動物醫院就診,以真實自體凝集現象確診為原發性免疫性溶血性貧血之患犬,共31隻。統計患犬的基本資料顯示,當患犬年齡超過8歲時,其死亡率顯著提升(p=0.03)。將患犬依治療結果分為存活及死亡兩組後,比較兩組患犬初就診的血檢發現,存活組的血小板總數顯著高於死亡組,而出現血管內溶血的比例、總膽紅素及BUN的數值則顯著低於死亡組。而經治療48小時後發現,存活組的血小板總數上升、總膽紅素濃度顯著下降、BUN下降,且血管內溶血的現象消失。相對而言,死亡組則發現血小板總數下降、總膽紅素濃度顯著升高且BUN升高,而血管內溶血現象不會消失。此結果顯示,患犬於治療期間,血小板總數,總膽紅素與BUN值及血管內溶血,可用來評估治療的成效。 31隻IMHA患犬中,有19隻於治療過程中給予hIVIG(Group 1),而12隻則未給予hIVIG(Group 2)。經過治療後,Group 1之存活率(63%)顯著高於Group2之存活率(25%)(p=0.04)。其次,group1中就診時出現血管內溶血現象之患犬,有7隻(group 1a),而未出現的則有12隻(group1b),而group2中就診時出現血管內溶血現象之患犬,有8隻(group 2a),而未出現的則有4隻(group 2b)。經治療後Group 1b有10隻存活,存活率為83% (10/12),而Group 2b僅1隻存活,存活率則為25% (1/4),此存活率於兩組間有顯著差異(p=0.03)。 總結,影響患犬預後之相關因子包含,年齡,血小板總數,血管內溶血現象,總膽紅素及血中尿素氮值,且若患犬經48小時之治療後發現,血小板總數上升、血管內溶血現象消失、總膽紅素及BUN數值下降,則預後較佳。本研究使用高劑量hIVIG治療19隻原發性IMHA患犬,證實給予hIVIG,可有效提升患犬長期存活率,且為一安全有效之治療方式。 | zh_TW |
dc.description.abstract | Immune-mediated hemolytic anemia (IMHA) is one of the most common anemic disease in dogs. Clinically, dogs with severe IMHA were often dead before the conventional immunosuppressive drugs become effective. Therefore, finding a therapy to immediately control immune response is important. The aims of our study were to find prognostic factors and evaluate the therapeutic efficacy of human intravenous immunoglobulin (hIVIG) in dogs with autoagglutination.
31 dogs diagnosed as canine IMHA by anemia and true autoagglutination at NTUVH during the period between April 2006 and April 2013 were collected in this study. The result suggest that, the mortality of dogs older than 8 years old was significantly higher (p =0.03). These 31 cases were divided into two groups, survival group (n=15) and non-survival group (n=16). The number of platelet count of survival group was significantly higher than non-survival and the probability of intravascular hemolysis, total bilirubin, BUN levels of survival group were significantly lower than the non-survival group at admission. After treatment for 48 hours, the number of platelet increased, the BUN and total bilirubin decreased and the intravascular hemolysis disappear in survival group. In contrast, the number of platelets decreased, the BUN and total bilirubin increased and the intravascular hemolysis was persistent in non-survival group. Based on these resuslt, the plate counts, BUN, total bilirubin and intravascular hemolysis were useful in the assessment of the treatment efficacy. The dogs in the group 1 (n=19) were treated with the combination of human intravenous immunoglobulin (hIVIG) and other immunosuppressive drugs. While dogs in group 2 (n=12) were only treated with immunosuppressive drugs. In group 1, 7 dogs were presented with intravascular hemolysis (group1a) and 12 dogs were not (group 1b). In group 2, 8 dogs had been detected intravascular hemolysis (group 2a) and 4 dogs had not (group 2b). The survival rates were 63 % (12/19) and 25% (3/12) for group 1 and group 2, and 83% (10/12) and 25% (1/4) for group1b and group 2b, respectively. There were significant differences in survival rate between group 1 and group 2, group 1b and 2b (p=0.04, p=0.03). In conclusion, the prognostic factors of dogs with IMHA included age, platelet counts, intravascular hemolysis, BUN and total bilirubin. The increase of platelet count, decreases of BUN and total bilirubin level and the remission of intravascular hemolysis after 48 hours of treatment suggest better prognosis. This study also proved that combined treatment with hIVIG have a better efficacy based on the better long-term survival rate. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T10:13:32Z (GMT). No. of bitstreams: 1 ntu-102-R99643005-1.pdf: 665018 bytes, checksum: f344c316a0b1444b22dcbdd754205547 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 目錄 i
表次 iii 圖次 iv 摘要 v Abstrsact vii 第一章、序言 1 第二章 文獻探討 2 第一節 犬免疫性溶血性貧血的介紹 2 1.1定義與分類 2 1.2 流行病學 2 1.3 致病機轉 3 第二節 臨床特徵 5 第三節 診斷 5 3.1 臨床病理學 5 3.2 確診方式 7 第四節 犬免疫性溶血性貧血的治療與預後 8 4.1治療 8 4.1.1糖皮質激素 8 4.1.2 其他免疫抑制藥物 9 4.1.3 靜脈注射人類免疫球蛋白 10 4.1.4 支持療法 12 4.1.5 脾臟切除術 12 4.2 預後 13 第三章 材料與方法 15 第一節 動物來源 15 第二節 IMHA預後因子之分析 15 2.1資料蒐集 15 第三節 治療方式與治療成效評估 16 3.1 人類靜脈注射免疫球蛋白之來源及施打方式 16 3.2 其他治療 16 3.3 靜脈注射人類免疫球蛋白副作用之評估 17 第四節 統計分析 17 第四章、結果 18 第一節 基本資料 18 第二節 臨床表現 18 第三節 實驗室檢查 19 3.1 血液學檢查 19 3.2 血清生化學檢查 20 第四節 hIVIG治療成效及副作用之評估 20 4.1治療成效 20 4.2 hIVIG施打劑量與副作用 21 第五章、討論 22 參考文獻 …….28 附表.............................................................................................................................37 附圖.............................................................................................................................43 | |
dc.language.iso | zh-TW | |
dc.title | 犬免疫性溶血性貧血:
I. 預後因子之評估 II. 靜脈注射人類免疫球蛋白治療效果之評估 | zh_TW |
dc.title | Canine Immune-mediated Hemolytic Anemia:
I. Evaluation of the Prognostic Factors II. The Therapeutic Efficacy of Human Intravenous Immunoglobulin | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周濟眾,陳文英,李雅珍 | |
dc.subject.keyword | 犬免疫性溶血性貧血,靜脈注射人類免疫球蛋白,真實自體凝集,預後因子,血管內溶血, | zh_TW |
dc.subject.keyword | Immune-mediated hemolytic anemia,human intravenous immunoglobulin,autoagglutination,prognostic factors,intravascular hemolysis, | en |
dc.relation.page | 47 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-08-20 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
顯示於系所單位: | 臨床動物醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 649.43 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。